NASDAQ:IDXG - Interpace Diagnostics Group Stock Price, Forecast & News

Interpace Diagnostics Group trades on the NASDAQ under the ticker symbol "IDXG."

Interpace Diagnostics Group Inc (NASDAQ:IDXG) released its earnings results on Wednesday, November, 13th. The business services provider reported ($0.19) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.19) by $0.00. The business services provider earned $7.73 million during the quarter, compared to the consensus estimate of $10 million. Interpace Diagnostics Group had a negative return on equity of 58.48% and a negative net margin of 77.55%. View Interpace Diagnostics Group's Earnings History.

Interpace Diagnostics Group is scheduled to release their next quarterly earnings announcement on Tuesday, March 17th 2020. View Earnings Estimates for Interpace Diagnostics Group.

Interpace Diagnostics Group issued an update on its FY 2020 After-Hours earnings guidance on Monday, November, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $$50-50 million, compared to the consensus revenue estimate of $$52.44 million.

3 equities research analysts have issued 12 month target prices for Interpace Diagnostics Group's stock. Their forecasts range from $2.00 to $15.00. On average, they anticipate Interpace Diagnostics Group's share price to reach $6.67 in the next year. This suggests that the stock has a possible downside of 24.2%. View Analyst Price Targets for Interpace Diagnostics Group.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Interpace Diagnostics Group in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Interpace Diagnostics Group.

News stories about IDXG stock have trended very negative on Tuesday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Interpace Diagnostics Group earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned news stories about the business services provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Interpace Diagnostics Group.

Interpace Diagnostics Group saw a drop in short interest in January. As of January 31st, there was short interest totalling 137,700 shares, a drop of 90.8% from the January 15th total of 1,500,000 shares. Based on an average daily volume of 51,200 shares, the short-interest ratio is currently 2.7 days. Currently, 4.3% of the company's shares are sold short. View Interpace Diagnostics Group's Current Options Chain.

Some companies that are related to Interpace Diagnostics Group include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), BioScrip (BIOS), Davita (DVA), Chemed (CHE), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), R1 RCM (RCM), CorVel (CRVL), Tivity Health (TVTY), The Providence Service (PRSC) and Cross Country Healthcare (CCRN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Interpace Diagnostics Group investors own include Histogenics (HSGX), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), Magnegas Applied Tchnlgy Sltns (MNGA), SCYNEXIS (SCYX), Advanced Micro Devices (AMD), Genocea Biosciences (GNCA), Trevena (TRVN), Netflix (NFLX) and Verastem (VSTM).

Interpace Diagnostics Group's stock is owned by a number of of retail and institutional investors. Top institutional investors include Perkins Capital Management Inc. (60.10%), Essex Investment Management Co. LLC (17.52%), Virtu Financial LLC (2.26%), Cambridge Investment Research Advisors Inc. (1.44%) and UBS Group AG (0.48%). View Institutional Ownership Trends for Interpace Diagnostics Group.

IDXG stock was sold by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc.. View Insider Buying and Selling for Interpace Diagnostics Group.

IDXG stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC, Essex Investment Management Co. LLC, UBS Group AG and Cambridge Investment Research Advisors Inc.. View Insider Buying and Selling for Interpace Diagnostics Group.

Shares of IDXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IDXG stock can currently be purchased for approximately $8.80.

Interpace Diagnostics Group has a market capitalization of $33.62 million and generates $21.90 million in revenue each year. The business services provider earns $-12,190,000.00 in net income (profit) each year or ($4.30) on an earnings per share basis. Interpace Diagnostics Group employs 89 workers across the globe.View Additional Information About Interpace Diagnostics Group.

The official website for Interpace Diagnostics Group is http://www.interpacediagnostics.com/.

Interpace Diagnostics Group's mailing address is MORRIS CORPORATE CENTER 1 BUILDING C 300 INTERPACE PARKWAY, PARSIPPANY NJ, 07054. The business services provider can be reached via phone at 855-776-6419 or via email at [email protected]